Omvoh is a prescription biologic medicine used to treat adults with moderate to severe ulcerative colitis and adults with moderate to severe Crohn's disease.

INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh ® (mirikizumab …

Omvoh (mirikizumab-mrkz) is an interleukin-23p19 antagonist indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Omvoh is a prescription medication indicated for the treatment of adults with moderately to severely active ulcerative colitis.

INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab …

4 days ago · Eli Lillys Omvoh gains FDA approval for treating moderately to severely active Crohns disease, offering long-term remission and visible intestinal healing.

Oct 27, 2023 · With a new FDA approval, Lilly’s mirikizumab has become the first IL-23 inhibitor to enter the crowded ulcerative colitis field, which is already occupied by biologic drugs from …

Oct 14, 2024 · When stacked up against Johnson & Johnson’s Stelara, Eli Lilly's Omvoh prompted histologic responses in more patients with moderately to severely active Crohn's …

OMVOH™ (mirikizumab-mrkz) injection, for intravenous or subcutaneous use, Lilly. 1 FDA approves Lilly's Omvoh™ (mirikizumab-mrkz), a first-in-class treatment for adults with …

Oct 16, 2023 · Omvoh (mirikizumab) is an interleukin-23p19 antagonist indicated for the treatment of moderately to severely active ulcerative colitis in adults. Omvoh selectively targets the p19 …